TGFB1 and neoplasm: In a recent clinical study, patients with relapsed Hodgkin lymphoma were treated with EBV-specific T cells engineered to express dnTGFβRII, and 4/8 patients showed an objective clinical response (228), demonstrating that TGFβ-resistant tumor-specific T cells can persist safely in patients and potentially enhance the efficacy of T cell immunotherapy.